

## REMARKS

Claims 1-36 were originally filed in this application. Amendments to claims 2-4, 6-7, 10-11, 13-14, 17-19, 22-23, 29-30, 33-36 are made in response. Claims 8-9, 15-16, 20-21, 24-28 have been canceled without prejudice or disclaimer. Consequently, claims 1-7, 10-14, 17-19, 22-23, and 29-30, and 33-36 are still pending in this application.

In the amendment, the "R<sup>2</sup>" in claim 3 is further defined. In claim 3, the " $\text{-C(=O)(CH}_2\text{)}_n\text{CO}_2$ " of the definition of R<sup>1</sup> is amended to " $\text{-C(=O)(CH}_2\text{)}_n\text{CO}_2\text{H}$ ". It is an obvious error. Additionally claims 7-11, 14-18, 19-28, and 30-34 are amended to methods claims and the scope of claims 7-11, 14-18, 19-28, and 30-34 are further limited.

### *Claim Objections*

The Examiner has objected to Claim 29 as being dependent on a rejected base claim. Claim 29 has been amended to include all of the limitations of that claims to be placed in allowable form.

### *Claim Rejections - 35 U.S.C. § 101 and 112*

The Examiner has rejected claims 7-11, 14- 18, 19-28, and 30-34 under 35 U.S.C. § 102 for providing for a use, but not setting forth any steps involved in the method. Claims 7-11, 14-18, 19-28, and 30-34 are amended to methods for treatment of diseases to more clearly define the subject matter of the claims.

### *Claim Rejections - 35 U.S.C. § 112*

The Examiner has rejected claims 7-11, 14- 8, 19-28, and 30-34 under 35 U.S.C. § 112 first paragraph for providing for a use, but not setting forth any steps involved in the method. Claims 7-11, 14-18, 19-28, and 30-34 are amended to more clearly define and limit the subject matter of the claims.

EXAMPLE 11 and EXAMPLE12 proved the effect for treatment of inflammatory diseases of WDY compounds; EXAMPLE 14 and EXAMPLE 15 proved the effect for treatment of arthritis of WDY compounds; and EXAMPLE 16 proved the effect for

prevention of organ rejection of WDY compounds. As the specification enables the person skilled in the art to perform the claims as amended, Applicants respectfully request that the Examiner withdraw the 35 U.S.C. 112 rejections.

The Examiner has rejected claims 2, 4, 6, 13, and 35-36, and 30-34 under 35 U.S.C. § 112 second paragraph for being indefinite. The claims have been amended to more clearly illustrate the reaction step by showing the chemical formula involved in the reaction step. The preamble of the claim has also been amended to prevent any confusion.

### ***Claim Rejections - 35 U.S.C. § 102***

The Examiner has rejected Claim 3 under 35 U.S.C. § 102 as being anticipated by Wang et al. (WO 00/63212) and also by Zhang et al., Yaoxue Xuebao, 1992, Vol. 27(11).

As stated above, the "R<sup>2</sup>" in claim 3 is further defined. The amended claim 3 is new over Zhang et al.

WO 00/63212 does not disclose the compound (wherein R<sub>1</sub> is alkyl having 1-4 carbon atom(s), -C(=O)(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H, wherein n is an integer of 1-4, wherein R<sub>2</sub> is -SCN) specifically. WO 00/63212 only mentions that the R<sub>2</sub> may be -SCN, however does not provide any specific examples regarding preparation of the compound, let alone the spectroscopic data or physicochemical parameters of the compounds. Therefore, the compounds mentioned in WO 00/63212 are only regarded as "table compounds", which will not destroy the novelty of the application. The amended claim 3 is new over WO 00/63212. (The inventor of WO 00/63212 is also the inventor of the application)

In view of above, the amended claim 3 possesses novelty.

### ***Conclusion***

Applicant has fully responded to each matter of substance raised in the Office Action and believes that the case is in condition for allowance. Withdrawal of the rejections and allowance of the application is therefore courteously solicited. Should the Examiner have any requests, questions or suggestions, the Examiner is invited to contact Applicant's attorney at the number listed below.

The Commissioner is authorized during the prosecution of this application to charge fees that may be required or credit any overpayment to Deposit Account No. 50-2638. Please ensure that our Attorney Docket No. 58260-011600 with any credit or charge to our Deposit Account.

Respectfully submitted,

GREENBERG TRAURIG, LLP

Date: September 20, 2006

By: 

R. Joseph Foster  
Reg. No. 56,953

Customer Number 33717  
GREENBERG TRAURIG, LLP  
2450 Colorado Avenue, Suite 400E  
Santa Monica, CA 90404  
Phone: (310) 586-6565  
Fax: (310) 586-0565  
E-mail: laipmail@gtlaw.com